Citation

  • Authors: Chen, D., Li, Y., Mei, Y., Geng, W., Yang, J., Hong, Q., Feng, Z., Cai, G., Zhu, H., Shi, S., Bai, X. Y., Chen, X.
  • Year: 2014
  • Journal: Cell Mol Life Sci 71 4027-42
  • Applications: in vitro / mimic miRNA, mimic miRNA and DNA cotransfection, siRNA / jetPRIME
  • Cell type: Rat mesangial cells

Abstract

The main pathological characteristic of glomerulonephritis is diffuse mesangial cell proliferation. MiR-34a is associated with the proliferation of various organs and cancer cells. However, the role of miR-34a in renal proliferation diseases is not clear. Therefore, this study aimed to elucidate the mechanism of miR-34a in the regulation of renal mesangial cell proliferation. The miR-34a expression level at different time points in an anti-Thy1 mesangial proliferative nephritis rat model was determined by qRT-PCR. The cell proliferation rate and cell cycle changes were measured in the in vitro cultured rat mesangial cells (RMCs). Our results suggested that miR-34a expression was negatively correlated with the degree of cell proliferation in the anti-Thy1 nephritis model. MiR-34a could extend the G0/G1 phase and block cell proliferation in RMCs. Dual-luciferase assay results showed that there were binding sites of miR-34a at 3'-UTR of platelet-derived growth factor receptor-beta (PDGFR-beta). MiR-34a can inhibit PDGFR-beta protein expression at a post-transcriptional level, suppress Ras/MAPK signaling pathways, and down-regulate expression of cell cycle proteins at the G0/G1 phase, such as cyclin D1, CDK4/CDK6. In addition, miR-34a may also inhibit RMC proliferation by directly targeting cyclin E and CDK2. MiR-34a inhibits exogenous stimuli-induced proliferation of mesangial cells. Expression levels of phospho-PDGFR-beta and phospho-MEK1 (an important downstream molecule in PDGFR-beta-induced signaling pathway) were significantly increased in the anti-Thy-1 nephritis rat model. These results suggest that miR-34a may regulate RMC proliferation by directly inhibiting expressions of PDGFR-beta, MEK1, and cell cycle proteins, cyclin E and CDK2.

Go to